TY - JOUR
T1 - Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing
T2 - NO
AU - van Kempen, Zoé L. E.
AU - Hogenboom, Laura
AU - Killestein, Joep
N1 - Funding Information: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Z.K. and L.H. report no disclosures. J.K. reports speaking and consulting relationships with Biogen, Genzyme, Merck, Novartis, Roche, Sanofi, and TEVA. Amsterdam UMC, location VUmc, MS Center Amsterdam has received financial support for research activities from Biogen, Celgene, Genzyme, Merck, Novartis, Roche, Sanofi,and TEVA.
PY - 2022/4/1
Y1 - 2022/4/1
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85122748779&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/34994665
U2 - https://doi.org/10.1177/13524585211064441
DO - https://doi.org/10.1177/13524585211064441
M3 - Comment/Letter to the editor
C2 - 34994665
SN - 1352-4585
VL - 28
SP - 693
EP - 695
JO - Multiple sclerosis (Houndmills, Basingstoke, England)
JF - Multiple sclerosis (Houndmills, Basingstoke, England)
IS - 5
ER -